Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Access to healthcare

Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

Editor's pick
Treatment Action Group
28 February 2014
Access to healthcare

Fighting For Global Access to Hepatitis C Therapies

Editor's pick
HepMag
19 February 2014
Hepatitis C treatment

Treating HCV -- Is the Price Right?

Editor's pick
Med Page Today
19 February 2014
New & experimental hepatitis C treatment

The deadly toll of drug-approval drag

Editor's pick
Winnipeg Free Press
14 February 2014
New & experimental hepatitis C treatment

Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Editor's pick
Bloomberg Businessweek
13 February 2014
Hepatitis C treatment

The global AIDS response can help in fighting hepatitis C

Editor's pick
Washington Post
13 February 2014
New & experimental hepatitis C treatment

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

Editor's pick
Gilead press release
11 February 2014
Hepatitis C transmission & prevention

Georgia Launches Programme to Curb Hepatitis

Editor's pick
Institiute for War & Peace Reporting
10 February 2014
New & experimental hepatitis C treatment

New hepatitis C pill lifts Gilead's 4Q sales

Editor's pick
Bloomberg Businessweek
7 February 2014
Hepatitis C treatment

Victrelis (boceprevir) label changes update contraindications and drug interactions

Editor's pick
FDA
23 January 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Gilead press release
17 January 2014
New & experimental hepatitis C treatment

Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Editor's pick
Bristol-Myers Squibb press release
8 January 2014
Hepatitis C treatment

Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Editor's pick
Seeking Alpha
3 January 2014
New & experimental hepatitis C treatment

Gilead to seek okay for combo hepatitis C pill in first quarter

Editor's pick
Reuters
18 December 2013
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Editor's pick
Gilead press release
18 December 2013
Access to healthcare

How patent rules could keep new hepatitis C drug from saving 'millions of lives'

Editor's pick
Global Post
18 December 2013
New & experimental hepatitis C treatment

An interview with Professor Jean-Michel Pawlotsky on how the treatment of HCV infection will change in the near future

Editor's pick
Hepatitis B & C Public Policy Association
17 December 2013
New & experimental hepatitis C treatment

Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

Editor's pick
Reuters
16 December 2013
Hepatitis C treatment

EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus

Editor's pick
Eurekalert Inf Dis
9 December 2013
Activism & civil society

Ukraininan HIV patients’ organisation is first-ever NGO to get PR award

Editor's pick
Ukrainian Community Advosory Board
28 November 2013
Hepatitis C symptoms & diagnosis

AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Editor's pick
HIVandhepatitis.com
28 November 2013
New & experimental hepatitis C treatment

Gilead responds over India patent pressure on HCV drug

Editor's pick
PharmaTimes
27 November 2013
New & experimental hepatitis C treatment

Meeting report of the International multi-stakeholders meeting on the compassionate use of HCV treatment

Editor's pick
EATG
26 November 2013
New & experimental hepatitis C treatment

European Medicines Agency advises on compassionate use of daclatasvir

Editor's pick
European Medicines Agency
26 November 2013